Email This

New Directions in the Management of Stroke: Optimizing Care Patient by Patient CME

Howard Kirshner, MDAuthor Information and Disclosures

Release Date: June 9, 2008; Valid for credit through August 10, 2008

Credits Available

Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Contents of This CME Activity

New Directions in the Management of Stroke: Optimizing Care Patient by PatientHoward Kirshner, MD

Go to CME Test Questions

Legal Disclaimer

The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.

This activity has expired.
The accredited provider can no longer issue certificates for this activity. Medscape cannot attest to the timeliness of expired CME activities.
CME Information

Learning Objectives

Upon completion of this activity, participants should be able to:

explain the high risk of atherothrombotic events associated with both stroke and transient ischemic attack (TIA),
discuss therapeutic strategies to decrease cardiac and peripheral vascular risks and improve outcomes in patients with stroke, and
examine evidence from clinical trials that support the use of cardiovascular agents in certain patient populations.

Author Disclosures

Howard Kirshner, MD
Disclosure: Sources of Funding for Research: Boehringer Ingleheim GmbH; Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; National Institutes of Health; Pfizer Inc
Consulting Agreements: Novartis AG
Financial Interests/Stock Ownership: None
Speakers' Bureau/Honorarium Agreements: Boehringer Ingleheim GmbH; Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; Forest Laboratories, Inc; Novartis AG; Ortho-McNeil, Inc; Pfizer Inc
Discussion of Off-Label, Investigational, or Experimental Drug Use: Combined aspirin/clopidogrel

This activity is provided by the Discovery Institute of Medical Education.

The Discovery Institute of Medical Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Please note that the course is certified only for physicians (MD, DO, or equivalent). All other participants receive a certificate of completion.

Contact This Provider